Publikationen von Udo Reichl

Alcalá Orozco, E. A.; Huber, N.; Klamt, S.; Rexer, T.; Reichl, U.: Development of a cell-free enzymatic cascade for the synthesis of GDP-fucose - modeling and optimization. GlycoBioTec 2023, Berlin, Germany (2023)

Dogra, T.; Pelz, L.; Rüdiger, D.; Hein, M. D.; Baelkner, M.; Julia D. Boehme, J. D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y. et al.; Reichl, U.: Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 32^nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)

Dogra, T.; Pelz, L.; Rüdiger, D.; Hein, M. D.; Baelkner, M.; Julia D. Boehme, J. D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y. et al.; Reichl, U.: Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 8^th European Congress of Virology, Gdańsk (Poland) (2023)

Hoang Son, T.; Lange, F.; Rexer, T.; Reichl, U.: Multi-gram-scale production of uridine nucleotide sugars by in-vitro multi-enzyme cascades. GlycoBioTec 2023, Berlin, Germany (2023)

Hoang Son, T.; Wormstall, S.-T.; Rexer, T.; Reichl, U.: Development of an in-vitro multi-enzyme cascade for the synthesis of uridine diphosphate N-acetylgalactosamine using a DoE approach. GlycoBioTec 2023, Berlin, Germany (2023)

Juárez-Osorio, M.; Darr, A.; Volckmar, J.; Bruder, D.; Rexer, T.; Reichl, U.: Towards full control over protein glycosylation: in-vitro glycoengineering of influenza A virus hemagglutinin and SARS-CoV-2 spike protein. GlycoBioTec 2023, Berlin, Germany (2023)

Küchler, J.; Opitz, P.; Kupke, S. Y.; Genzel, Y.; Benndorf, D.; Reichl, U.: Absolute quantification of viral proteins during single-round replication of vaccine producer cell lines. 32^nd Annual Meeting of the Society for Virology (GfV) , Ulm (Germany) (2023)

Küchler, J.; Opitz, P.; Kupke, S. Y.; Genzel, Y.; Benndorf, D.; Reichl, U.: Absolute quantification of influenza A virus proteins during single-round replication in vaccine producer cell lines. 16^th PEACe (Protein Expression in Animal Cells) Conference, Sitges (Spain) (2023)

Lemke, G.; Zuniga-Banuelos, F. J.; Grote, V.; Hoffmann, M.; Rapp, E.; Reichl, U.: N-glycan Sulfation on Human IgA: In-Depth N-glycoproteomic Analyses of Sulfated N-glycan Site-Specificity and Distribution on Human IgA Isotypes. GlycoBioTec 2023, Berlin, Germany (2023)

Pelz, L.; Dogra, T.; Boehme, J.D.; Hein, M. D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y.; Reichl, U.: Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)

Pelz, L.; Dogra, T.; Boehme, J.D.; Marichal-Gallardo, P.; Hein, M. D.; Genzel, Y.; Bruder, D.; Kupke, S. Y.; Reichl, U.: A Scalable High-Yield Process for Production of Influenza A Virus Defective Interfering Particles and In Vivo Studies. Himmelfahrtstagung on Bioprocess Engineering 2023, Weimar (Germany) (2023)

Pelz, L.; Dogra, T.; Boehme, J.D.; Marichal-Gallardo, P.; Hein, M. D.; Genzel, Y.; Bruder, D.; Kupke, S. Y.; Reichl, U.: Influenza A Virus Chimeric OP7 Defective Interfering Particles: Cell Culture-based Production and In Vivo Antiviral Efficacy. 32^nd Annual Meeting of the Society for Virology (GFV), Ulm (Germany) (2023)

Piasecka, J.; Rüdiger, D.; Kupke, S. Y.; Reichl, U.: Reduced transcription of the mutated genomic segment 7 of the novel “OP7” influenza defective interfering particle intended for use as an antiviral. 8^th European Congress of Virology, Gdańsk (Poland) (2023)

Piasecka, J.; Rüdiger, D.; Kupke, S. Y.; Reichl, U.: Promoter mutations in novel “OP7” influenza defective interfering particle severely reduce transcription of its genomic segment 7. 32^nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)

Piasecka, J.; Rüdiger, D.; Kupke, S. Y.; Reichl, U.: Promoter mutations in the novel “OP7” influenza defective interfering particle intended for use as antiviral. 17^th Vaccine Congress, Glasgow (Scotland) (2023)

Rexer, T.; Alcalá Orozco, E. A.; Hoang Son, T.; Kleeberg, S.; Reichl, U.: Platform for the scalable synthesis of human milk oligosaccharides. The Origins and Benefits of Biologically Active Components in Human Milk Conference, Florida, USA (2023)

Sultan Mohideen, M. A. H.; Khesali Aghtaei, H.; Reichl, U.; Benndorf, D.: Development of a packed foam bed bioreactor for biological methanation. 6th International Conference on Monitoring and Control of Anaerobic Digestion Processes, Leipzig, Germany (2023)

Wenzel, L.; Ruhnau, J.; Hoffmann, M.; Rexer, T.; Reichl, U.: Synthesis of Synthetic Lipid-Linked Oligosaccharides for In-Vitro Glycoengineering of Hemagglutinin Peptides by a Cell-Free, Multi-Enzyme Cascade. GlycoBioTec 2023, Berlin, Germany (2023)

Zuniga-Banuelos, F. J.; Hoffmann, M.; Budimir, I.; Reichl, U.; Rapp, E.: New avenues for human blood plasma biomarker discovery via improved in-depth analysis of the low-abundant N-Glycoproteome. GlycoBioTec 2023, Berlin, Germany (2023)

Alcalá Orozco, E. A.; Hoang Son, T.; Rexer, T.; Reichl, U.: In vitro multi-enzyme cascades for the synthesis of nucleotide sugars. INTERfaces Conference on ‘Intensifying Biocatalytic Processes – From Enzyme and Material Design to Industrial Applications’ (IBPRO2022), Bielefeld, Germany (2022)